LogicBio Therapeutics Inc (LOGC)


Stock Price Forecast

Nov. 16, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading LogicBio Therapeutics Inc chart...

About the Company

LogicBio Therapeutics is a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood. The company's proprietary GeneRide™ platform is a new approach to precise gene insertion that harnesses a cell's natural DNA repair process leading to durable therapeutic protein expression levels. LogicBio's cutting-edge sAAVy™ capsid development platform is designed to support development of treatments in a broad range of indications and tissues. The company is based in Lexington, MA.

CEO

Frederic Chereau

Exchange

NASDAQ

Website

www.logicbio.com

$32M

Total Revenue

39

Employees

$68M

Market Capitalization

-0.39

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $LOGC News

AstraZeneca pays record 660% premium for gene editing company LogicBio

1y ago, source: pharmaphorum

As per the agreement, Alexion will initiate a cash tender offer through a subsidiary to acquire all outstanding shares of LogicBio for $2.07 per share, a rare 660% premium on LogicBio’s share price.

LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the Ameri...

1mon ago, source: ADVFN

LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio or the Company), a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, today announced ...

AstraZeneca pays 660% premium for gene therapy firm LogicBio

1mon ago, source: FXEmpire.com

The Market News Today: Social Media Giants on Edge as Supreme Court Weighs Internet LawsTue, 27 Feb 2024 09:57:47 GMT Asia Market News: Markets React as BoJ Considers Exit, China’s Economy ...

Endeavour Silver Stock (NYSE:EXK), Quotes and News Summary

3y ago, source: Benzinga.com

Gainers LogicBio Therapeutics, Inc. (NASDAQ: LOGC) shares surged 637.6% to close at $2.01 on Monday after the company announced it will be acquired by AstraZeneca's subsidiary, Alexion ...

BCLI Brainstorm Cell Therapeutics Inc.

13d ago, source: Seeking Alpha

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases.

CARISMA Therapeutics Inc CARM

16h ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Cara Therapeutics Inc CARA

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

TRDA Entrada Therapeutics, Inc.

23h ago, source: Seeking Alpha

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform ...

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023

24d ago, source: Yahoo Finance

Warning! GuruFocus has detected 8 Warning Signs with MCRB. On March 5, 2024, Seres Therapeutics Inc (NASDAQ:MCRB) released its 8-K filing, announcing the fourth quarter and full year financial ...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

27d ago, source: Yahoo Finance

Last week saw the newest full-year earnings release from Amicus Therapeutics, Inc. (NASDAQ:FOLD), an important milestone in the company's journey to build a stronger business. The statutory ...

Intellia Therapeutics, Inc.

5mon ago, source: CNN

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms ...

Monopar Therapeutics Inc

3mon ago, source: CNN

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...